Early research (Phase 1)Study completedNCT04231747
What this trial is testing
CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Who this might be right for
Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
Juno Therapeutics, a Subsidiary of Celgene 24